High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Aldesleukin (Primary) ; Dinutuximab beta (Primary) ; Busulfan; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Interleukin-2; Isotretinoin; Melphalan; Vincristine
- Indications Neuroblastoma
- Focus Registrational; Therapeutic Use
- Acronyms SIOPEN
- 28 Jul 2023 According to a Recordati media release, to obtain FDA approval of a Biologics License Application (BLA) for the registration of Qarziba in the United States, preparatory activities are ongoing for a Type C Meeting with the FDA, expected in second half of 2023.
- 06 Jun 2023 Results (n=414) assessing risk factors and outcomes for patients < 18 months with MNA neuroblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 22 Dec 2021 This trial has been completed in Slovenia (Global end date: 31 Mar 2018).